(COLL) Collegium Pharmaceutical, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(COLL) Collegium Pharmaceutical, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Collegium Pharmaceutical, Inc. 4P's Marketing Mix Analysis summarizes the company’s product offerings, pricing strategy, distribution channels, and promotional tactics to show how it competes in specialty pharmaceuticals. The page includes a real preview/sample of the analysis so you can evaluate format and depth before buying; purchase the full version for the complete ready-to-use report.
Product
Xtampza ER oxycodone
Xtampza ER is Collegium Pharmaceutical, Inc.’s flagship brand and an extended-release oral oxycodone for severe, persistent pain that needs daily, around-the-clock opioid therapy. Its DETERx abuse-deterrent platform is the key Product edge, helping set it apart in a market still shaped by opioid-risk scrutiny. In 2025, it remained the core pain asset for Collegium, anchoring the company’s commercial mix and payer access strategy.
Nucynta ER tapentadol
Nucynta ER tapentadol is an extended-release opioid for moderate to severe chronic pain, built to provide sustained analgesia for long-duration pain. It sits in Collegium Pharmaceutical, Inc.'s branded pain portfolio and supports the company’s focus on prescription pain therapies. For the 2025 fiscal year, use of extended-release dosing remains key in chronic pain care because it reduces peak-trough swings versus short-acting options.
Nucynta IR tapentadol
Nucynta IR is Collegium Pharmaceutical, Inc.'s immediate-release tapentadol for acute pain and short-term dosing, giving prescribers a non-oxycodone branded option in pain care. It pairs with Nucynta ER, which extends tapentadol coverage for longer pain management. Tapentadol is a Schedule II opioid in the U.S., so the brand sits in a tightly managed market.
Jornay PM methylphenidate
Jornay PM is a delayed-release, extended-release methylphenidate for ADHD that is taken in the evening and built for next-day symptom control. It gives Collegium Pharmaceutical, Inc. a clear move beyond pain and into central nervous system therapy.
In the 4P's mix, the Product fits a niche use case: overnight release, morning coverage, and once-daily dosing. That matters in ADHD care, where timing and adherence drive outcomes.
- Evening dosing for morning coverage
- ADHD-focused CNS expansion
- Delayed-release, extended-release formulation
- Supports once-daily use
DETERx abuse-deterrent platform
DETERx is Collegium Pharmaceutical, Inc.'s core abuse-deterrent platform in Xtampza ER, and it helps make the oxycodone product harder to crush, snort, or inject. That matters because Xtampza ER is still a key revenue driver for Collegium Pharmaceutical, Inc., so the platform is both a safety feature and a moat.
- Built into Xtampza ER
- Blocks common abuse methods
- Supports product differentiation
- Helps defend revenue share
Collegium’s 2025 Portfolio: Pain Leadership and ADHD Growth
Collegium Pharmaceutical, Inc.’s Product mix in 2025 centered on pain and CNS drugs: Xtampza ER used DETERx abuse-deterrence, Nucynta ER and Nucynta IR covered chronic and acute pain, and Jornay PM expanded the portfolio into ADHD. The lineup is built around once-daily or timed-release dosing, with Xtampza ER remaining the lead commercial asset.
| Product | Role |
|---|---|
| Xtampza ER | Flagship pain brand |
| Nucynta ER/IR | Branded pain coverage |
| Jornay PM | ADHD expansion |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of Collegium Pharmaceutical, Inc.’s Product, Price, Place, and Promotion strategies for practical strategic insight.
Editable Excel File
Distills Collegium Pharmaceutical, Inc.’s 4P’s Marketing Mix Analysis into a quick, decision-ready snapshot that eases planning and alignment.
Reference Sources
Provides a concise, traceable bibliography of industry reports, FDA filings, and financial statements to speed due diligence and verify Collegium Pharmaceutical assumptions.
Place
United States prescription market
Collegium Pharmaceutical, Inc. sells only in the U.S. prescription market, so its commercial footprint is fully U.S.-centric. In FY2025, the Company generated about $700 million in net product sales, with patients reaching therapy through licensed prescribers and pharmacies across the U.S. prescription channel.
Wholesaler distribution
Collegium Pharmaceutical, Inc. uses standard pharmaceutical wholesale channels, so products move through large distributors before reaching dispensing pharmacies. This model fits branded prescription medicines and supports national inventory flow with broad market coverage. Three U.S. wholesalers—McKesson, Cencora, and Cardinal Health—anchor most drug distribution, which helps keep access steady.
Retail pharmacy access
Collegium Pharmaceutical, Inc. reaches patients mainly through community retail pharmacies, where prescriptions are filled only after clinician authorization. This gives medicines like Xtampza ER and BELBUCA broad day-to-day access in the U.S. pharmacy channel. In 2025, this route supported steady patient refill flow and helped convert prescriber demand into pharmacy pickup.
Specialty and mail-order channels
Collegium Pharmaceutical, Inc. uses specialty and mail-order channels for branded therapies like JORNAY PM, which can help covered patients get therapy faster and keep refills on track. Specialty drugs are only about 2% of U.S. prescriptions but roughly 50% of drug spend, so access control matters.
These channels also help manage prior authorization and reduce refill gaps, which is useful for chronic use medicines. The tradeoff is tighter payer control, but it can support steadier demand and fewer abandoned scripts.
- Improves access for covered patients
- Supports prior authorization
- Helps manage refill timing
Stoughton Massachusetts headquarters
Collegium Pharmaceutical, Inc.'s headquarters in Stoughton, Massachusetts anchors its U.S. operations, with corporate, commercial, and administrative functions based there. In 2025, the Company reported net product revenues of $670.4 million, and the Stoughton hub supports the team that manages this scale of national business. The site matters for the Place part of the mix because it centralizes decision-making close to core U.S. markets.
- Stoughton = U.S. headquarters
- Hosts corporate and commercial teams
- Supports 2025 revenue of $670.4 million
Collegium’s U.S.-Only Prescription Reach Drove $700M in FY2025 Sales
Collegium Pharmaceutical, Inc. keeps Place focused on the U.S. prescription channel, with all sales flowing through U.S. wholesalers, pharmacies, and specialty or mail-order paths. In FY2025, net product sales were $700 million, and net product revenues were $670.4 million, showing a national but U.S.-only reach.
| Place factor | FY2025 data |
|---|---|
| Geography | U.S. only |
| Net product sales | $700 million |
| Net product revenues | $670.4 million |
| Key channels | Wholesaler, retail, specialty |
Get Your Copy
Collegium Pharmaceutical, Inc. Reference Sources
The preview shown here is the exact, full Collegium Pharmaceutical, Inc. 4P’s Marketing Mix analysis you’ll receive instantly after purchase—no samples or teasers, fully editable and ready to use for strategy, valuation, or presentation purposes.
Promotion
Field sales to prescribers
Collegium Pharmaceutical, Inc. leans on field sales to healthcare professionals, with reps focused on pain specialists, primary care doctors, and other prescribers. This channel is built to lift brand awareness and push prescribing consideration at the point of care. The model matters in a market where trust and specialty access drive scripts, so the sales team stays close to key prescribers.
Clinical and disease education
Collegium Pharmaceutical, Inc. uses clinical and disease education to frame pain as a real functional need, while differentiating Xtampza ER through its abuse-deterrent, microsphere oxycodone formulation. The messaging helps prescribers compare features that matter in long-term opioid therapy and supports informed prescribing decisions. This is key in a market where Xtampza ER remains one of Collegium Pharmaceutical, Inc.’s core branded assets.
Market access outreach
Collegium Pharmaceutical, Inc. uses market access outreach to work with payers and pharmacy benefit managers on formulary placement, prior auth, and coverage terms. That matters for branded controlled-substance therapies, where one coverage change can decide whether a patient gets the drug at the counter. U.S. prescription drug spend topped $600 billion, so access work can move real volume.
Patient support programs
Collegium Pharmaceutical, Inc. uses copay and access support for eligible patients, which lowers out-of-pocket pain and cuts delays at the pharmacy counter. That matters because even small access barriers can break therapy starts and hurt adherence, so support programs help more patients stay on treatment.
- Copay help reduces upfront cost friction.
- Access support speeds pharmacy approval.
- Better access supports start and adherence.
Digital and congress presence
Collegium Pharmaceutical, Inc. uses digital channels and medical congresses to extend its sales force reach and keep clinicians exposed to brand messages beyond one-on-one calls. In 2024, Collegium reported $787.7 million in net revenues, so this low-friction promotion mix matters for scale and awareness.
Medical meetings help keep product data in front of prescribers, while digital content supports repeat touchpoints with stakeholders. The setup is built to reinforce recall and stay visible where prescribing decisions are discussed.
- Digital extends sales coverage
- Congresses support clinician engagement
- Both strengthen brand awareness
Collegium’s Promotion Play: Driving Xtampza ER Demand and Access
Collegium Pharmaceutical, Inc. promotes mainly through specialty sales reps, payer outreach, copay support, and digital plus congress visibility. In 2024, net revenue was $787.7 million, so promotion is built to protect Xtampza ER demand and improve access where prescribing and coverage decisions meet.
| Channel | Role |
|---|---|
| Field sales | Drive HCP detail calls |
| Payer access | Support formulary placement |
| Copay aid | Reduce patient cost friction |
| Digital and congresses | Extend brand reach |
Price
Premium branded pricing
Collegium Pharmaceutical, Inc. prices its medicines as branded prescription products, so they sit well above generic commodity levels. The value case comes from clinical differentiation and formulation features like abuse-deterrent, extended-release delivery; in 2024, Xtampza ER and Belbuca remained its core branded pain assets. This premium model supports higher revenue per script, not volume-driven discounting.
Rebate-based payer access
Collegium Pharmaceutical, Inc. uses rebate-based payer access to win insurer and PBM formulary coverage, so net pricing is lower than list price after rebates and contract discounts. That means gross-to-net deductions matter as much as headline price. In practice, coverage gains can support volume even when the realized price per fill is lower.
Copay support
Collegium Pharmaceutical, Inc. offers copay support for eligible commercially insured patients, which lowers out-of-pocket cost at the point of sale. That can help more prescriptions get filled on the first try, especially when cost is the main barrier. It also supports faster start rates for therapy.
Patient assistance programs
Collegium Pharmaceutical, Inc. uses patient assistance programs to keep branded medicines reachable for uninsured or underinsured patients. These programs can lower or remove out-of-pocket cost, which matters because even a $35 monthly copay can block fill rates for chronic therapy.
- Helps bridge coverage gaps
- Supports access for eligible patients
- Common branded-pharma pricing tool
- Can improve script persistence
For Collegium Pharmaceutical, Inc., this pricing lever protects access when insurance is thin, while still preserving the brand value of its medicines. It is most useful where payer mix is uneven and patient affordability can drive drop-off.
Nucynta generic pressure
Nucynta faces generic tapentadol competition, which usually cuts net price and limits branded pricing power. For Collegium Pharmaceutical, Inc., the defense is access and contracting, since broader formulary coverage can help hold volume even when rivals pressure price. In a generic-heavy channel, unit growth often matters more than list price.
- Generic tapentadol raises price pressure.
- Access deals help protect volume.
- Formulary coverage matters more than list price.
Collegium’s Brand Pricing Holds, But Rebates and Generics Trim Gains
Collegium Pharmaceutical, Inc. keeps Price premium on branded pain drugs like Xtampza ER and Belbuca, so value comes from formulation, not discounting. Rebates and gross-to-net cuts lower realized price, but help secure formulary access. Copay support and patient aid reduce out-of-pocket cost and can lift fill rates. Nucynta faces generic tapentadol pressure, which limits pricing power.
| Price lever | Effect |
|---|---|
| Premium list price | Brand value |
| Rebates | Net price down |
| Copay aid | Access up |
| Generics | Price pressure |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.